FDA
-
-
-
-
-
-
-
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
-
-
-
-
-
-
-
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
-
-
-
-
-
-
-
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
-
-
-
-
-
-
-
Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs
-
-
-
-
-
-
-
FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action - Hagens Berman
-
-
-
-
-
-
-
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
329,911 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

